Improving the knowledge and science of our pharmaceutical medicinal cannabis
Bod is in collaboration with various research institutes to investigate the safety and efficacy of our pharmaceutical-grade medicinal cannabis. This research will help support patient care, practitioner knowledge and public health initiatives.
Studies Currently Open For Recruitment
Bod Open-Label Observational Study (BodOLOS) – Australia
If you are eligible for our prescription medicines, you may also be able to participate in our observational study.
This study will help build evidence in the use of medicinal cannabis using ‘real-world’ data, allowing the doctor to practice as they would normally, and the patients to live as they would normally too. The study ‘observes’ patient outcomes, using scientifically validated data collection.
Patients who are prescribed Bod pharmaceutical medicines, with the approval of the Therapeutic Goods Administration (TGA’s), may be invited to participate in this important observational study. The aim of this study is to assess the safety, tolerability and efficacy of Bod’s pharmaceutical medicinal cannabis therapy in patients for the prescribed indication.
Visit one of the approved study sites listed below to register your interest, and mention this study
Project Twenty21 – UK
Project Twenty21 aims to create the largest body of evidence for the efficacy of medicinal cannabis. The initiative will use collated data to support policy makers as they review medicinal cannabis availability, and affordability for patients who would benefit from its use. The project will assist prescribers operating in private practice and advance the potential for UK Government Health (NHS) funding. Project Twenty21 will focus on these conditions:
- Anxiety Disorder
- Chronic Pain
- Multiple Sclerosis (MS)
- Post-Traumatic Stress Disorder (PTSD)
- Substance Use Disorder (as a harm reduction strategy)
- Tourette’s Syndrome
Bod Medicinal Cannabis will be included in this landmark study. If you are in the UK and meet the selection criteria you may be eligible in participating.
Motor Neurone Disease Clinical Trial – Australia
Gold Coast University Hospital in Australia is conducting a randomised double-blind, single-centre phase 3 trial is to assess the safety, tolerability and efficacy of a Bod pharmaceutical-grade medicinal cannabis in improving the symptoms and slowing the progression of disease in motor neurone disease (MND) patients, also referred to as Amyotrophic lateral sclerosis (ALS). The study team aims to treat thirty (30) patients over a period of six months to evaluate the potential protective mechanisms of cannabis that could help to delay disease progression.
If you have MND you may be able to participate in this trial at the Gold Coast University Hospital, QLD. The study will include comprehensive neurological and diagnostic assessments at no cost to approved participants. Participants will be assigned by chance (a process called randomisation) to receive either medicinal cannabis or placebo. Treatment will continue for 180 days (6 months), with a commitment to taking the medication every day for this period. You will be seen every 3 months in the research clinic, located at the Gold Coast University Hospital. Monthly telephone calls will occur between these clinic visits. This study will not interfere with any other medication you are taking at the time and you will remain under the care of your primary physicians.
To be considered for inclusion in the study you need to:
- Have a probable or definite diagnosis of MND
- Be between the ages of 25 and 75
- Have symptom onset within the past two years
Exclusion criteria and further details on this research, ‘Efficacy of Cannabinoids in Amyotrophic Lateral Sclerosis or Motor Neurone Disease (EMERALD Study)’, can be found on the Australian and New Zealand Clinical Trials Registry (ANZCTR) site, here.
This research will provide preliminary data on whether medicinal cannabis has an effect on the progression of MND. Research is ongoing and there are currently no completed studies that have looked at cannabis as a treatment to delay MND progression and prolong survival in humans.
To register your interest please email study co-ordinator, Mr Berzenn Urbi, at Berzenn.Urbi@health.qld.gov.au
Phase 1 Clinical Research
Bod Australia has invested in pharmaceutical quality phase 1 clinical research to assess the safety, tolerability and pharmacokinetics of the 5% CBD oil and innovation wafer. The research was conducted at the Nucleus Network.
- 2019. A Novel Standardized Cannabis sativa L. Extract and Its Constituent Cannabidiol Inhibit Human Polymorphonuclear Leukocyte Functions
- 2019. Cannabis sativa L. extract and cannabidiol inhibit in vitro mediators of skin inflammation and wound injury.
Exploring Potential Clinical Applications
Research of the Bod full-spectrum product (50mg CBD/mL) is currently underway with the University of South Australia, School of Pharmacy and Medical Sciences.
The study will provide valuable information for clinical practice, future research and assist in ongoing product development.